Login to Your Account

Emerging Markets

'No Exit' on Chinese Markets Despite Relaxing of IPO Ban

By Shannon Ellis
Contributing Writer

Monday, June 24, 2013

SHANGHAI, China – Chinese biopharmaceutical companies are unlikely to benefit much from a relaxation in an 8-month-old ban on new initial public offerings (IPOs) or from new draft regulations aimed at improving disclosures and governance.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription